Undisclosed CDK4 inhibitor / TYK Medicines - LARVOL DELTA

Development of a novel selective CDK4 inhibitor for HR+/HER2- breast cancer (AACR 2026) - "It also exhibited synergistic antitumor effects when combined with fulvestrant, with good tolerability evidenced by stable animal body weight throughout the study. Preliminary in vitro combination studies revealed that pairing the selective CDK4 inhibitor with a CDK2 inhibitor or a PI3K inhibitor produced significant synergistic inhibitory effects on MCF7 and palbociclib-resistant MCF7 cells. Optimization of the lead compound is ongoing with the goal of identifying a preclinical candidate (PCC) for IND-enabling studies.# Apeng Liang and Meihua Li contributed equally to this work.* Correspondence authors."

Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2